Emerging Biopsychosocial Models of Care for Psychostimulant Disorder Prevention and Treatment

Psychostimulants remain a concern for providers and communities across the country as overdose rates continue to climb and treatment options remain limited. The use of psychostimulants and associated mortality is intertwined with the opioid epidemic and the fact that stimulant use disorder (StUD) remains one of the few substance use disorders without an FDA-approved pharmacological intervention. As a result, providers and stakeholders are increasingly utilizing a biopsychosocial approach to identification, treatment, and management of this complex and serious condition, and there remain opportunities to enhance the complementary approaches to care and policy related to StUD.